Curated News
By: NewsRamp Editorial Staff
August 18, 2026
Nanox AI's HealthOST Enters UK Market via Vertec Reseller Deal
TLDR
- Nanox gains exclusive UK market access for HealthOST via Vertec, enhancing its competitive position in medical imaging.
- HealthOST uses AI to analyze routine CT scans for spinal osteoporosis, with FDA clearance and UKCA/CE marking.
- The NICE recommendation enables NHS use of HealthOST, aiding early osteoporosis detection and improving patient outcomes.
- HealthOST is among five AI tools recommended by NICE to spot vertebral fractures during routine CT scans.
Impact - Why it Matters
This partnership is crucial because it brings an FDA-cleared and NICE-recommended AI tool to the UK, potentially improving early detection of osteoporosis and vertebral fractures in routine CT scans. With the NHS under pressure, such technology can enhance diagnostic accuracy, reduce costs, and improve patient outcomes, making it a significant step in preventive healthcare.
Summary
Nanox (NASDAQ: NNOX), a leader in innovative medical imaging technology, has taken a significant step to expand its AI-driven healthcare solutions in the United Kingdom. The company announced that its subsidiary, Nanox AI Ltd., has entered into a sales reseller agreement with Vertec Scientific Ltd. for the commercialization of its Nanox.AI bone solution, HealthOST. Under the agreement, Vertec will have an exclusive license to market and resell HealthOST in the UK, with a minimum annual license commitment, for an initial three-year term. HealthOST is an FDA-cleared and UKCA/CE-marked AI software that analyzes routine CT scans to support clinicians in evaluating musculoskeletal diseases of the spine, including osteoporosis. This move comes on the heels of a recommendation by the National Institute for Health and Care Excellence (NICE) in November 2025, which endorsed HealthOST and its predecessor, HealthVCF, among five AI technologies for use by the National Health Service (NHS) to aid in the opportunistic detection of vertebral fragility fractures.
The agreement with Vertec Scientific Ltd. is a strategic move to leverage Vertec's established presence in the UK medical device market to bring HealthOST to a broader audience. Vertec is a well-known distributor of diagnostic imaging and radiotherapy products, and this partnership is expected to accelerate the adoption of HealthOST within the NHS and private healthcare sectors. The NICE recommendation is particularly impactful as it validates the clinical utility of the AI solution and opens doors for reimbursement and integration into standard care pathways. This development underscores Nanox's commitment to expanding its global footprint and advancing preventive healthcare through early detection of chronic conditions.
Nanox's ecosystem includes the Nanox.ARC, a cost-effective 3D multi-source digital tomosynthesis imaging system; Nanox.AI, a suite of AI algorithms for routine CT interpretation; Nanox.CLOUD for secure data management; and other solutions like Nanox.MARKETPLACE and USARAD Holdings for teleradiology services. The company's vision is to make medical imaging more accessible and efficient, and this partnership is a key milestone in achieving that goal in the UK market. Investors and stakeholders can find the latest news and updates regarding NNOX in the company's newsroom at http://ibn.fm/NNOX. The full press release is available at https://ibn.fm/VBSS4.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Nanox AI's HealthOST Enters UK Market via Vertec Reseller Deal
